GRIN2B and treatment resistant depression: One trial of traxoprodil (CP-101, 606), another GluN2B-selective antagonist, was, however, stopped because of obvious dissociative side effects in some patients during infusion as well as cardiotoxicity [170], though it had exhibited anti-depressant effects in treatment-resistant depression (TRD) patients with a 60% level in response [171].